长效的葡萄糖反应性胰岛素具有快速开始作用的作用
Wei Liu1, Juan Zhang1, Yanfang Wang1
1State Key Laboratory of Advanced Drug Delivery and Release Systems, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; Jinhua Institute of Zhejiang University, Jinhua 321299, China.
概括
研究人员开发了用于糖尿病管理的可注射葡萄糖反应性胰岛素配方 (GRIF). 这些配方在血糖升高时提供快速胰岛素释放,通过更少的注射改善血糖控制.
科学领域:
- 生物材料科学 生物材料科学
- 内分泌学 在内分泌学.
- 制药技术 制药技术 制药技术
背景情况:
- 目前的胰岛素疗法需要频繁注射,影响患者的坚持和血糖控制.
- 开发葡萄糖敏感胰岛素旨在模仿天然胰岛素分泌机制,提供按需的葡萄糖调节.
- 从长效配方中快速释放和吸收胰岛素对于有效降低葡萄糖至关重要.
研究的目的:
- 开发可注射的长效葡萄糖敏感胰岛素配方 (GRIF),以改善糖尿病管理.
- 为了实现顺序,快速的胰岛素释放和即时吸收,以迅速开始作用.
- 在临床前模型中评估GRIF的疗效和安全性.
主要方法:
- 合成的葡萄糖胺修饰的胰岛素阿斯巴特 (ASP-Gn) 和酸修饰的多氨酸 (PLL-FPBA).
- 通过复合ASP-Gn和PLL-FPBA来创建一个皮下储库,形成注射GRIF.
- 在1型糖尿病小鼠和小猪模型中评估了体外葡萄糖反应性胰岛素释放和体内血糖控制.
主要成果:
- 优化的GRIF配方在体外显示出更优异的葡萄糖反应性胰岛素释放.
- 在糖尿病小鼠和迷你猪模型中,GRIF表现出迅速开始作用并有效控制血糖水平.
- 在研究的动物模型中没有观察到可辨认的毒性.
结论:
- 可注射的长效葡萄糖敏感胰岛素配方 (GRIF) 显示出降低注射频率和改善血糖控制的前景.
- 开发的GRIF技术能够快速,由葡萄糖触发的胰岛素释放和吸收,模仿生理性胰岛素分泌.
- 格里夫代表了一种潜在的更安全,更有效的替代方案,以传统的胰岛素治疗1型糖尿病.
相关概念视频
01:27Insulin Formulations: Types and Delivery
143
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
143
01:06Oral Hypoglycemic Agents: Glinides
111
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
111
01:24Glucagon-like Receptor Agonists
266
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
266
01:16Insulin: Dosing Regimen and Adverse Effects
127
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
127
01:25Insulin: Biosynthesis, Chemistry, and Preparation
318
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
318
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
140
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
140